Acellular vaccines for preventing whooping cough in children

Zhang, Linjie; Prietsch, Sílvio O. M.; Axelsson, Inge; Halperin, Scott A.

doi:10.1002/14651858.cd001478.pub6

Cited by 98 publications

(61 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Efficacy also varies between aP products. A 2011 Cochrane review found aP vaccines containing ‡3 components provide greater protection than aP vaccines with fewer components [61]. Thus when considering the comparative effectiveness of aP and wP vaccines, the heterogeneity in products needs to be considered.…”

Section: Wp and Ap Efficacy And Effectivenessmentioning

confidence: 99%

“…Thus when considering the comparative effectiveness of aP and wP vaccines, the heterogeneity in products needs to be considered. Considering the limited and variable efficacy and effectiveness data available for wP vaccines, the Cochrane review concluded that ‡3 component aP were more effective than low-efficacy wP vaccines, but may be less effective than the highest-efficacy wP vaccines [61]. Efficacy and effectiveness studies for aP and wP vaccines have varied in design, case definition, case ascertainment, vaccination schedule and period of follow-up, limiting the ability to directly compare results between studies [57].…”

Section: Wp and Ap Efficacy And Effectivenessmentioning

confidence: 99%

See 1 more Smart Citation

Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine: recent epidemiology

Sheridan

Frith

Snelling

et al. 2014

Expert Review of Vaccines

105

View full text Add to dashboard Cite

The recent epidemics of pertussis (whooping cough) in parts of the USA and Australia have led to the largest numbers of annual cases reported in over half a century. These epidemics demonstrated a new pattern, with particularly high rates of disease among pre-adolescents and early adolescents. These high rates of pertussis coincided with the first cohorts vaccinated with purely acellular pertussis vaccine, which replaced whole-cell pertussis (wP) vaccine in the later 1990s in the USA and Australia. Studies undertaken during these epidemics provide new evidence of more rapid waning of acellular pertussis-containing vaccines and longer-term protection from effective wP-containing vaccines. There is evidence that receiving wP as at least the first dose of pertussis-containing vaccine provides greater and more long-lived protection, irrespective of the nature of subsequent doses. This evidence will be reviewed together with the immunobiology associated with both vaccines, and the implications for pertussis control discussed.

show abstract

Section: Wp and Ap Efficacy And Effectivenessmentioning

confidence: 99%

Section: Wp and Ap Efficacy And Effectivenessmentioning

confidence: 99%

Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine: recent epidemiology

Sheridan

Frith

Snelling

et al. 2014

Expert Review of Vaccines

105

View full text Add to dashboard Cite

show abstract

“…The first studies published described HHE following a whole-cell pertussis vaccine [1][2][3] ; a Cochrane review 11 showed that the risk of hypotonic-hyporesponsive episodes was significantly lower in acellular vaccine recipients compared with those immunised with whole-cell vaccines. Our cohort did not allow us to make a comparison between the 2 vaccines, but seems to confirm that the cellular pertussis components are not the only factor involved in HHE.…”

Section: Discussionmentioning

confidence: 99%

Hypotonic-hyporesponsive episodes after administration of hexavalent DTP-based combination vaccine: A description of 12 cases

Vigo

Costagliola

Ferrero

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Hypotonic-hyporesponsive (HHE) episodes are known and recognized phenomena, which typically occur within 48 hours of immunisation..Our aim is to describe 12 cases of HHE brought to the Center of Pediatric Sleep Medicine, with attention to the clinical features of the episode and their follow-up. Medical charts of infants visited between 2005-2015 were reviewed. Twelve infants showed a HHE using HHE using Brighton Collaboration Criteria. All infants received a Hexavalent diphtheria -tetanus -pertussis acellular component -hepatitis B-,inactivated poliovirus-Haemophilus influenzae type-b conjugate vaccine. Five out of 12 were brought to Emergency Department, where 2 were symptomatic (one was hyporeactive, the other had fever). No infant died during the episode, or the follow-up, nor developed neurological disease after subsequent vaccinations. HHE are confirmed as benign events, even after administration of hexavalent vaccination, devoid of negative neuropsychomotor outcome.

show abstract

“…Protective efficacy is defined as prevention of infections, as defined, occurring 30 days after the third immunization. Systematic reviews have shown that three-and five-component acellular vaccines are equally or more effective than whole-cell vaccines against pertussis, which in turn are more effective than one-or two-component acellular vaccines (Zhang et al, 2012). Thus, systemic immunization with acellular pertussis vaccines incorporating multiple virulence factors involved in adherence and mucosal infection have clinical efficacy against B. pertussis infection comparable or superior to that provided by the killed whole-cell vaccine.…”

Section: Vaccinementioning

confidence: 99%